SCHEMBL5595153

SCHEMBL5595153

COc1ccc(NC(=O)Nc2cc(-c3ccccc3)ccc2O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.58
KMT2A Q03164 3/20 0.58
POLB P06746 3/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
HDAC1 Q13547 3/20 0.58
KDM4E B2RXH2 2/20 0.58
APOBEC3A P31941 1/20 0.58
GFER P55789 1/20 0.58
APOBEC3G Q9HC16 1/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
NPC1 O15118 5/20 0.58
MAPT P10636 1/20 0.58
PKM P14618 3/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
MEN1 O00255 2/20 0.55
IDO1 P14902 1/20 0.54
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5594888 0.89 HDAC1 (0.67) HDAC1KDM4EAPOBEC3AGFERAPOBEC3G
SCHEMBL8899001 0.85 TP53 (0.60) RAB9AKMT2AKDM4ESMN1; SMN2NPC1
SCHEMBL5605083 0.85 MEN1 (0.59) RAB9AKMT2APOLBHDAC1KDM4E
SCHEMBL5664848 0.82 CA12 (0.65) RAB9AKMT2APOLBHDAC1KDM4E
SCHEMBL5595113 0.81 POLB (0.64) RAB9AKMT2APOLBKDM4ESMN1; SMN2
SCHEMBL11106394 0.79 RAB9A (0.85) RAB9AKMT2APOLBKDM4ESMN1; SMN2
SCHEMBL3676161 0.79 GRIK1 (0.73) POLBCA12CA1CA2CA9
SCHEMBL5595819 0.78 MAPT (0.55) RAB9AKDM4ENPC1MAPTCA12
SCHEMBL7947558 0.78 HDAC1 (0.56) RAB9AKMT2AHDAC1KDM4EAPOBEC3A
SCHEMBL7491718 0.77 SMN1; SMN2 (0.61) RAB9AKMT2APOLBCTDSP1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0809492-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2007-01-24 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
US-6180675-B1 THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND SMITHKLINE BEECHAM CORPORATION 2001-01-30 US disclosed
US-6005008-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-12-21 US disclosed
US-5886044-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-03-23 US disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
EP-0809492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1996025157-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN RAB9A 1746/4885KMT2A 3978/4885POLB 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.